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Early profiles of clinical evolution after intravenous
thrombolysis in an unselected stroke population
M G Delgado,1 P Michel,2 M Naves,1 P Maeder,3 M Reichhart,2 M Wintermark,4
J Bogousslavsky5
ABSTRACT
Background Intravenous recombinant tissular
plasminogen activator (rt-PA) is the only approved
pharmacological treatment for acute ischaemic stroke.
The authors aimed to analyse potential causes of the
variable effect on early course and late outcome.
Methods and results 136 patients (42% women, 58%
men) treated with intravenous rt-PA within 3 h of stroke
onset in an acute stroke unit over a 3-year period, were
included. Early clinical profiles of evolution at 48 h were
divided into clinical improvement (CI) (decrease >4
points in the National Institute of Health Stroke Scale
(NIHSS)); clinical worsening (CW) (increase >4 points
NIHSS); clinical worsening after initial improvement
(CWFI) (variations of >4 points in the NIHSS). Patients
with clinical stability (no NIHSS modification or <4
points) were excluded. The patients showed in 66.9% CI,
13.2% CW 8.1 % CWFI and 11.8% remained stable.
Female sex, no hyperlipaemia and peripheral arterial
disease were associated with CW. Male sex and smoking
were associated with CI. Absence of arterial occlusion on
admission (28.4%) and arterial recanalisation at 24 h
were associated with CI. Main causes of clinical
deterioration included symptomatic intracranial
haemorrhage (sICH), persistent occlusion and cerebral
oedema. 23.5% developed ICH, 6.6% of which had sICH.
At 3 months, 15.5% had died. Mortality was increased in
CW, mainly related to sICH and cerebral oedema. The
outcome of CWFI was intermediate between CW and CI.
Conclusions Early clinical profiles of evolution in
thrombolysed patients vary considerably. Even with CI, it
is critical to maintain vessel permeability to avoid
subsequent CW.
INTRODUCTION
Intravenous recombinant tissular plasminogen
activator (rt-PA) has been approved in 1996 by the
Food and Drugs Administration for the USA and in
2002 by the European Medicines Agency for
Europe, for acute stroke treatment within 3 h of
stroke onset. After intravenous rt-PA treatment,
clinical evolution varies, with minimal or no
changes in clinical status, improvement or wors-
ening, sometimes after some clinical improvement.
The aim of our study was to analyse the causes of
these clinical proﬁles of evolution within 48 h after
intravenous rt-PA treatment in a thrombolysed
stroke population.
METHODS
We studied consecutive patients treated with
intravenous rt-PA at a University Hospital (Centre
Hospitalier Universitaire VaudoisdLausanne).
Inclusion criteria were ischaemic stroke in any
territory, age 18 years or older (if over 80 years old,
treatment depending on prestroke dependency and
comorbidity), onset to treatment time#3 h, cranial
tomography (CT) scan without haemorrhagic
lesion and neurological status $6 points in the
National Institute of Health Stroke Scale (NIHSS).
Exclusion criteria were similar to those used in the
NINDS study.1 The treatment was initiated in the
emergency department after the CT study, using
intravenous rt-PA (0.9 mg/kg). Non-contrast CT
scan and perfusion CT (P-CT) was performed prior
to the rt-PA treatment, whereas intracranial and
extracranial angio-CT was usually performed after
initiation of rtPA. A repeat CT scan and intra- and
extracranial angio-CTwere performed at 24 h after
the procedure and whenever the patient worsened.
If creatinine clearance was <30 ml/min using the
Cockroft formula (<50 ml/min if patient on
metformin), the patient was not given intravenous
contrast. If creatinine clearance was 30e50 ml/min,
the patient received 300 ml of isotonic sodium
chloride solution in30 min followed by 1 ml kg1 h1
over the following 12 h, and oral N-acetylcysteine
for 48 h. None of the patients who received contrast
medium developed renal failure.
The P-CTexamination consisted of two 40-series
at an interval of 5 min, each series consisting of one
image per second in cine mode during intravenous
administration of iodinated contrast material. The
acquisition parameters for both series were 80 kV
and 100 mA. For each series, CT scanning was
initiated 7 s after the injection of 50 ml iohexol at
a rate of 5 ml s1 into an antecubital vein with
a power injector. The time delay before contrast
material reached the brain parenchyma allowed the
acquisition of baseline images without contrast
enhancement. Multidetector-array technology
allowed data acquisition from two adjacent 10 mm
sections for each series. The two P-CT series thus
allowed data acquisition in four adjacent 10 mm
cerebral CT sections.2 The mean transit time map
results from a deconvolution of the parenchymal
timeeconcentration curves by a reference arterial
curve. The deconvolution operation requires a refer-
ence arterial input function, the selection of which
is automatically performed by the P-CT software.
The cerebral blood volume (CBV) map is inferred
from a quantitative measurement of the partial size-
averaging effect, which is absent at the centre of the
large superior sagittal venous sinus. A simple equa-
tion combining CBV and mean transit time (MTT)
values leads to the cerebral blood ﬂow (CBF) value.2
Penumbra and infarct maps can thus be inferred
from relative CBV and relative CBF maps. The
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cerebral and cervical CT angiography was performed from the
origin of the aortic arch branch vessels to the circle of Willis.
Carotid and transcranial duplex were carried out within 48 h
after admission. NIHSS, Barthel Index and modiﬁed Rankin Scale
(mRS) were used to assess clinical status and functional status.
Patients who died were given the worst possible score in clinical
scales such as the NIHSS. We used the TOAST3 criteria for stroke
aetiological classiﬁcation. Information on demographics, risk
factors and previous strokes was obtained from the patient, next
of kin and family physician. Pretreatment glycaemia, tempera-
ture, cholesterol, ﬁbrinogen, INR, platelet count, blood pressure
and haematocrit were recorded.
Clinical proﬁles of evolution within the ﬁrst 48 h were divided
into clinical improvement (CI), with a decrease of $4 points
NIHSS; clinical worsening (CW), with an increase of $4 points
NIHSS; and clinical worsening after initial improvement (CWFI),
with a decrease of $4 points NIHSS followed by an increase of
$4 points NIHSS. Patients with clinical stability (no NIHSS
modiﬁcation or <4 points in the NIHSS) were excluded. Patients
were observed clinically in a neurological intermediate care unit
on an hourly basis during the day and every 3 h at night. We
deﬁned intracranial symptomatic haemorrhage (sICH) as clinical
worsening of $4 points in the NIHSS best attributed to intra-
cranial haemorrhage. Any other ICH was considered as
asymptomatic (aICH).
We classiﬁed causes of clinical deterioration as symptomatic
intracranial haemorrhage (sICH), cerebral oedema, early stroke
recurrence deﬁned as an acute onset clinical worsening that was
best explained by a new ischaemic event after repeat radiological
evaluation, persistent arterial occlusion (or reocclusion) and
others (including systemic and unknown causes). Occlusion that
was still present at the neuroimaging control study at approxi-
mately 24 h was labelled ‘persistent arterial occlusion,’ although
we cannot exclude early recanalisation followed by reocclusion in
some patients.
Statistical analyses were performed with the SPSS v.13.0
software for Windows (SPSS, Chicago). Standard univariate
analyses (c2, t tests and ManneWhitney U test) were carried
out; and values were given as percentages, means and SD or
median and the IQR for descriptive purposes. KaplaneMeier
survival curves were used to examine crude survival. Cox
multiple regression analyses for censored survival data were
performed to compare survival between subjects with stable or
clinical worsening and patients with clinical improvement. This
multivariate analysis was also performed to determine the causes
of worsening. All analyses were adjusted according to age, sex,
onset to lysis, admission NIHSS, hyperlipaemia, diabetes
mellitus, high blood pressure (>140 mm Hg/90 mm Hg) and
smoking.
The P-CTand angio-CT protocol has been the standard of care
for patients with suspected acute supratentorial stroke since
2002 in our institution. The ethical committee for clinical
research of the University of Lausanne has approved the retro-
spective analysis of these patients.
RESULTS
A total of 136 patients fulﬁlling all criteria were treated: 57/136
(42%) women and 79/136 (58%) men. The mean age was
64.6 years (19e85). The mean stroke onset to ﬁbrinolysis time
was 150 min (CI 151 min; CW 143.6 min; CWFI 154.3). Aeti-
ology was cardioembolic in half of the patients. Early clinical
proﬁles were CI in 91/136 patients (66.9%), CW in 18/136
patients (13.2%) and CWFI in 11/136 patients (8.1%). Therefore,
of the 102 patients with initial clinical improvement, 11 (10.8%)
deteriorated in the following 48 h. The other 16/136 patients
(11.8%) remained stable according to our deﬁnitions.
Cerebrovascular risk factors
Female sex, no hyperlipaemia and peripheral arterial disease were
associated with CW within 48 h (p<0.05). Smoking was asso-
ciated with CI within 48 h (p<0.01). No correlation was found
with previous ischaemic stroke, cardiac disease or antithrombotic
treatment on admission (table 1).
Neuroimaging studies
Of the 136 patients, 119 (87.5%) had a good-quality P-CT prior
to thrombolysis. The P-CT study without perfusion deﬁcit or
more penumbra than infarct was related to CI. Still, 3/20
patients (15%) with a normal study and 21/95 patients (22.1%)
with more penumbra than core worsened within 48 h (table 2).
Of the 136 patients, 127 (93.3%) had good-quality angio-CTat
admission; angio-CTstudy was not possible for renal or technical
reasons in nine patients (6.6%) at admission and in four patients
(2.9%) at 24 h. On admission, 91/127 patients (71.6%) had intra-
and/or extracranial occlusion in the territory of the acute stroke
(table 3). Absence of arterial occlusion was associated with CI
(p<0.05). Angio-CT at 24 h showed recanalisation in 52/87
patients (59.7%) which was associated with CI (p<0.001).
Most patients (14/20 patients, 70%) with normal P-CT
showed no occlusion on angio-CT at admission, 1/20 patients
(5%) extracranial occlusion, 2/20 patients (10%) intracranial
occlusion and 1/20 patients (5%) extra- and intracranial
occlusion. Patients with core>penumbra (three patients) showed
arterial occlusion in angio-CT.
Clinical deterioration
In CW, the main causes of worsening were sICH in 6/18 patients
(33.3%), persistent arterial occlusion in 6/18 patients (33.3%) and
cerebral oedema in 6/18 patients (33.3%) (table 4). In CWFI, the
main cause of worsening was persistent arterial occlusion in 8/11
patients (72.7%), followed by systemic causes in 1/11 patients
(9%) and unknown causes in 2/11 patients (18.1%) (table 4).
Concerning the time of worsening, in CW, 15/18 patients
(83.3%) were within 24 h and 3/18 patients (16.7%) within
36e48 h. The exact time points of worsing were: ﬁve patients
during the ﬁrst 12 h (one at 3 h, two at 4 h, and two at 12 h);
10 patients in 12e24 h (eight at 12e24 h, two at 24 h); two
patients at 36 h; and one patient at 40 h. In CWFI, 10/11 patients
Table 1 Demographic and clinical variables and their relationship with
clinical evolution
NINDS ECASS ECASS II
Sex gender (female/male)
(percentage of patients)
42/58 42/58 35/65 39.3/61
Smoking (percentage of patients) 36 43
High blood pressure (percentage
of patients)
48 66 39.6 52.8
Diabetes mellitus (percentage of
patients)
16 24 11.8 21.3
Cardiac disease (percentage of patients)
Coronary disease 23 43 19.5 13.9
Valvular disease 8 11 3.2 0.2
Atrial fibrillation 27 18 17.5 21.8
Previous TIA/stroke (percentage
of patients)
29 39 27.3 27.6
Antithrombotic treatment
(percentage of patients)
26 41 12.5 20.5
NIHSS at admission (median) 16 14 12 11
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(90.9%) had initial worsening within 24 h, and 1/11 patients
(9.1%) one at 48 h. The exact time points of worsening before
improvement were: ﬁve patients during the ﬁrst 12 h (one at 2 h,
one at 3 h, one at 10 h, one at 12 h and one at 12 h); three patients
during 12e24 h; two patients at 24 h; and one patient 48 h.
Within 24 h, 32/136 patients (23.5%) had ICH, and 9/136
patients (6.6%) showed sICH.
Outcome at 3 months
At 3 months, 21/135 available for follow-up patients had died
(15.5%), 13 females and eight males. In these patients, stroke
aetiology was predominantly cardioembolic (52%).
Of the patients who died, two patients were in the CI group,
11 patients in the CW group and three patients in the CWFI
group (ﬁgure 1). Compared with the CI group, the multivariate
analysis showed a higher mortality risk in the CW group
(RR¼43.6, 95% CI 9.6 to 197.8) and in the CWFI group
(RR¼14.7, 95% CI 2.4 to 88.1).
The KaplaneMeier curve showed that mortality was higher in
sICH and oedema (ﬁgure 2). After adjustment for potential
confounders (age, sex, onset to lysis, admission NIHSS, hyper-
lipaemia, diabetes mellitus, high blood pressure and smoking),
the presence of sICH increased the risk of mortality (RR¼30.0,
95% CI 9.0 to 100.1). aICH was not associated with mortality. In
addition, the presence of oedema and persistent occlusion also
increased the mortality risk (RR¼29.1, 95% CI 8.6 to 97.7 and
RR¼4.3, 95% CI 1.0 to 17.4, respectively).
DISCUSSION
In this series of thrombolysed patients, we found that CW was
related to female sex, no hyperlipaemia and peripheral arterial
disease, whereas CI was related to male sex and smoking.
Moreover, CI was related to absence of arterial occlusion and
arterial recanalisation, whereas CW and CWFI were associated
with persistent arterial occlusion.
Cerebrovascular risk factors
Female gender was associated with early clinical worsening in our
study,which in turnwas associatedwith increasedmortality.This
is in line with a generally increased stroke mortality in women.4
This contrasts with reports of higher response to thrombolysis in
women in some studies5 6 but not in others.7
Our study supports previous observations of a beneﬁcial effect
of smoking on better functional outcome,8 although we have not
observed a protective role against. ICH.9
Absence of hyperlipaemia was correlated with CW, and there
were more patients without hyperlipaemia in the sICH group
(7:2). A neuroprotective effect of cholesterol has also been
postulated.10
Peripheral arterial disease is closely associated with coronary
and carotid atherosclerosis.11 The relationship with CW in our
study may be due to this association.
We did not ﬁnd any differences either in previous ischaemic
cerebrovascular events or in previous antithrombotic treatment
for early clinical evolution after intravenous thrombolysis.
Given the small number of patients examined in our study,
some correlations between clinical and radiological variable and
clinical evolution may be over- or underestimated.
Neuroimaging studies
In our patients, a normal perfusion study or a larger penumbra
than infarct volumewas correlated with CI. Still, nearly a quarter
of these patients had CW (sometimes after initial improvement).
Whereas patients with a large penumbra may beneﬁt more from
recanalisation, non-recanalisation in these patients may lead to
death of at-risk tissue,12e14 explaining CW or CWFI in some of
them. Cases have been described using P-CTas exclusion criteria
for intravenous thrombolysis treatment,15 intravenous throm-
bolysis within 3 and 6 h15 16 and in unknown stroke onset.17
We conﬁrmed previous observations that arterial recanalisa-
tion in angio-CTwas associated with CI.18 Similarly, mortality
Table 2 Perfusion-CT variables on admission and its relationship with
clinical evolution
Patients (%)
Clinically
stable
Clinical
improvement
Clinical
worsening
Clinical
worsening
after initial
improvement Total
Not done 2 (11.8) 12 (70.6) 2 (11.8) 1 (5.9) 17 (100)
Normal study 2 (10) 15 (75) 2 (10) 1 (5) 20 (100)
Penumbra>core 10 (10.5) 64 (67.4) 12 (12.6) 9 (9.5) 95 (100)
Core>penumbra 2 (50) 0 (0) 2 (50) 0 (0) 4 (100)
Table 3 Angio-CT variables on admission and its relationship with
clinical evolution
Patients (%)
Clinically
stable
Clinical
improvement
Clinical
worsening
Clinical
worsening
after initial
improvement Total
No arterial occlusion 2 (5.6) 31 (86.1) 2 (5.6) 1 (2.8) 36 (100)
Arterial occlusion 12 (13.1) 55 (60.4) 15 (16.4) 9 (9.8) 91 (100)
Table 4 Causes of clinical deterioration
Patients (%)
Clinical
worsening
Clinical
worsening
after initial
improvement Total
Intracranial haemorrhage 6 (33.3) 0 (0) 6 (20.6)
Cerebral oedema 6 (33.3) 0 (0) 6 (20.6)
Persistent arterial occlusion/new stroke 6 (33.3) 8 (72.7) 14 (48.2)
Systemic cause 0 (0) 1 (9) 1 (3.4)
Unknown cause 0 (0) 2 (18.1) 2 (6.8)
Total 100 100 100
Figure 1 Mortality at 3 months regarding clinical evolution. CI, clinical
improvement; CW, clinical worsening; CWFI, clinical worsening after
initial improvement.
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was greater at 3 months in patients with persistent occlusion at
24 h. We also found a greater tendency towards CI in patients
with MCA occlusions than in patients with associated internal
carotid artery (ICA) occlusions. ICA occlusions have been
described as being more resistant to intravenous treatment than
middle cerebral artery (MCA) occlusions,1 vertebral arteries and
basilar artery.18 Thrombus burden may explain this response.18
Persistent occlusion and arterial reocclusion correlates with
clinical deterioration, though the latter has a better prognosis
than the former, because a temporary recanalisation may allow
for a partial penumbra rescue.19
Early clinical deterioration and outcome at 3 months
Approximately 15% of patients with stroke (spontaneously or
after intravenous thrombolysis) may have worsening after initial
improvement.20 Clinical progression usually occurs within 48 h
but was seen as late as 96 h in 13% patients.21
In our study, cerebral oedema, sICH and persistent arterial
occlusion contributed equally with CW. Patients of this group
had the worst clinical and functional prognosis and greater
mortality at 3 months.
Any ICH was observed in 23.5% of patients, less than in the
ECASS studies (48.4% within the ﬁrst week in ECASS II22).
SICH as deﬁned by ECASS criteria was observed in 6.6% of
patients, somewhat more than in the ECASS-II. A correlation
was observed between no ICH and CI, and between ICH and CW.
Moreover, ICH and cerebral oedema patients had the worst
clinical and functional prognostic at 3 months. Among ICH,
aICH had no inﬂuence in the clinical prognosis.
Our patients with CWFI were characterised by persistent
arterial occlusion at 24 h and a better outcome than CW patients.
CWFI has been described in 13% of patients in the literature.
Arterial reocclusion1 is suspected as the main cause of CWFI.19
However, some authors did not ﬁnd any differences between
patients treated and those not treated with rt-PA in clinical
deterioration, which supports evidence against reocclusion.23 As
we did not perform early (<6 h) or continuous monitoring of the
arterial patency in our study, we do not know the frequency of
early recanalisation followed by reocclusion in our patients.
The improved functional prognosis in CWFI group as
compared with CW may be explained by penumbra rescue from
temporary recanalisation, as mentioned above.
CONCLUSIONS
We conclude that early clinical proﬁles of evolution after
intravenous rt-PA treatment in an unselected stroke population
vary considerably. It can be predicted by vascular risk factors,
perfusion patterns and arterial pathology. Patients with no
hypoperfusion or with large penumbras, and patients with early
and persistent recanalisation seem to have a more favourable
early and late outcome.
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